Dongcheng Pharmaceutical: Shanxi Nuclear Medicine Production Center Licensed to Operate

Dongcheng Pharmaceuticals announced that its wholly-owned subsidiary, AndiCo, received a "Radiopharmaceutical Production License" issued by the Shanxi Provincial Drug Administration. The Shanxi Jinzhong Nuclear Medicine Production Center has been approved to commence operations, with the product being Fluorine-18 Deoxyglucose Injection. The launch of this center will help AndiCo expand its market, increase revenue, and improve the nationwide network layout of nuclear medicine.